The Federal Court of Appeal (FCA) has dismissed an appeal concerning four actions related to the molecule apixaban under the Patented Medicines (Notice of Compliance) Regulations (Regulations). The Federal Court (FC) found the patents
FCA upholds selection patent protecting apixaban and rejects that a second patented invention was obvious to try
